Indian Pharmaceutical Alliance drops Sovaldi opposition

The Indian Pharmaceutical Alliance (IPA) has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi (sofosbuvir).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead faces fresh Sovaldi challenge

20 May 2015 Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

Asia

Indian drug makers end generic bids

18 April 2016 Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb.

Asia-Pacific

Gilead gets Sovaldi patent approval in India despite opposition

10 May 2016 Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.

More on this story

Americas

Gilead faces fresh Sovaldi challenge

20 May 2015 Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

Asia

Indian drug makers end generic bids

Asia-Pacific

Gilead gets Sovaldi patent approval in India despite opposition

10 May 2016 Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.

More on this story

Americas

Gilead faces fresh Sovaldi challenge

20 May 2015 Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

Asia

Indian drug makers end generic bids

Asia-Pacific

Gilead gets Sovaldi patent approval in India despite opposition

10 May 2016 Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.